Table 2.
Meta‐analysis Results for Loci That Reached or Marginally Reached Genomewide Significance (p < 5 × 10−8)
| Locus | SNP | EA | OA | EAF | Gene | Beta | SE | p Value | Q | Q_P | I 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CHR12:591300 | rs215226 | A | G | 0.597 | B4GALNT3 | 0.205 | 0.014 | 4.60 × 10−49 | 13.43 | 0.0038 | 0.777 |
| CHR18:33152792 | rs7241221 | G | A | 0.772 | GALNT1 | 0.109 | 0.017 | 4.40 × 10−11 | 0.955 | 0.812 | 0 |
| CHR8:119976256 | rs1485303 | G | A | 0.568 | TNFRSF11B | 0.074 | 0.014 | 7.70 × 10−08 | 6.416 | 0.093 | 0.532 |
Locus = chromosome and position of the single‐nucleotide polymorphism [SNP]; EA = effect allele; OA = other allele; EAF = effect allele frequency; gene = nearest gene to the sclerostin‐associated SNP; beta = SD change in serum sclerostin per effect allele; SE = standard error; heterogeneity test: Q = Cochrane's Q statistics; Q_P = Cochrane's Q p value; I 2 = I 2 statistics.